Corcept Therapeutics, Inc. USDC – Northern District of California febraury 24, 2026 CLASS PERIOD: october 31, 2024 – december 30, 2025Lead plaintiff Deadline: april 21, 2026 Please complete the form below to contact Kaplan Fox regarding the Corcept Therapeutics Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Principle Contacts Jeffrey P. Campisi JCampisi@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. According to the complaint, “Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”). The complaint further alleges that “Defendants’ Class Period representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA’s review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.” The complaint alleges that the “[t]he truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter . . . regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had ‘concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.’ The press release quoted Defendant Belanoff as stating that ‘[w]e are surprised and disappointed by this outcome.’ As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%.” WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes. If you have any questions about this investigation, please contact: CONTACT:Jeffrey P. CampisiKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(212) 329-8571jcampisi@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1501Oakland, California 94612(415) 772-4704lking@kaplanfox.com The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases. Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Oddity Tech Ltd. Shareholder Alert: Learn More Now See the Case Grail, Inc. Shareholder Alert: Learn More Now See the Case Kyndryl Holdings, Inc. See the Case Hub Group, Inc. See the Case Ralliant Corporation See the Case Beyond Meat, Inc. See the Case BlackRock TCP Capital Corp. See the Case Commvault Systems, Inc. See the Case REGENXBIO Inc. See the Case Navan, Inc. See the Case Nutanix, Inc. See the Case Lakeland Industries, Inc. See the Case
